---
{"type":"item","title":"ADVAXIS, INC. (XNAS:ADXS)","listId":60639,"itemKey":16,"position":5,"visibleItemTotal":194,"canonicalUrl":"https://listium.com/@allofus/60639/smallcapsummer/16/advaxis-inc-xnasadxs","listUrl":"https://listium.com/@allofus/60639/smallcapsummer","listTitle":"#SmallCapSummer","creator":{"id":"allofus","name":"All of Us Financial","url":"https://listium.com/@allofus"},"stats":{"views":3678,"likes":1},"category":"finance / investing","publishedAt":"2021-07-18T19:50:34.513Z","updatedAt":"2021-07-18T19:50:34.513Z","fields":[{"id":0,"name":"Company","type":"PrimaryText"},{"id":1,"name":"Approx. Price","type":"Number","format":"currency"},{"id":2,"name":"Symbol","type":"Selection","multi":false},{"id":4,"name":"Description","type":"Text","format":"short"},{"id":5,"name":"Industry","type":"Selection","multi":true},{"id":6,"name":"Price Group","type":"Selection","multi":false}]}
---

# ADVAXIS, INC. (XNAS:ADXS)

From [#SmallCapSummer](https://listium.com/@allofus/60639/smallcapsummer)  
By [All of Us Financial (@allofus)](https://listium.com/@allofus)

List stats: 3678 views · 1 like  
Published 18 July 2021 · Updated 18 July 2021

Category: finance / investing

- Approx. Price: $0.49
- Symbol: ADXS
- Description: Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
- Industry: Biotechnology & Medical Research
- Price Group: ~ $0.50